louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06375226: Autism and Attachment. An Explorative Study of Attachment Styles in Autistic Adults.
Official title: Autism Spectrum Disorder and Attachment. An Explorative Study of Attachment Styles in Adults With Autism Spectrum Disorder
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Autism Spectrum Disorder
Keywords: Autism Spectrum Disorder
Attachtment
Adults
Lead sponsor: Parnassia Groep
Sponsor class: OTHER
First posted: 2024-04-19
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults (\>18 years) with ASD, and without intellectual disability. Participants will be recruited from SARR Autism Rotterdam and Antes, both part of Parnassia Group in the Netherlands. SARR Autism Rotterdam is specialized in psychodiagnostic assessments and interventions for children, adolescents, and adults with ASD. Antes and Parnassia Group are multisite mental health institutes specialized in psychodiagnostic assessments and interventions for adults with a broad range of psychiatric disorders, including ASD.

Brief summary: The present study examines the relationship between attachment and autism spectrum disorder (ASD) in adults.

Detailed description: Rationale: Previous research on autism spectrum disorder (ASD) and attachment has improved understanding of the aetiology and development of the disorder. Research on adults with ASD, however is scarce. The study is focussed on attachment in adults with ASD. Objective: The aim of the current study is to explore attachment styles of adults with ASD and examining the relationship between attachment and ASD.

The study requires 60 participants.

Eligibility criteria: Inclusion Criteria:

* Inclusion criteria are:

  * a primary clinical diagnosis of DSM-5 ASD (APA, 2013)
  * age 18 - 65 years
  * no intellectual disability (IQ \> 80)

Exclusion Criteria:

* acute psychosis
* acute suicidality
* psychotic disorder
* intellectual disability (IQ \< 80)

Primary outcomes:
measure: The Social Responsiveness Scale - Adult version (SRS-A)
timeFrame: 15 minutes
measure: The Attachment Styles Questionnaire (ASQ)
timeFrame: 15 minutes
measure: Experiences in Close Relationships - Revised questionnaire (ECR-r)
timeFrame: 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Rotterdam
country: Netherlands
facility: ParnassiaGroep Antes
state: Zuid-Holland
Study officials:
affiliation: Parnassia Groep Antes
name: Richard Vuijk, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02077426: Heart Failure and Regional Specific Exercise Training Stimulus
Official title: Heart Failure and Regional Specific Exercise Training Stimulus
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Heart Failure
Sedentary
Keywords: Functional Capacity
Exercise Independence
Peripheral
Strength
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2014-03-04
Enrollment: 0
Sex: ALL
Minimum age (years): 55
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine whether heart failure patients can tolerate a four-weeks of a new exercise training regimen that targets peripheral tissues (Regional Specific Training Stimulus-RSTS) and has been show to produce significant benefits in aerobic capacity and strength in healthy subjects aged 70+years who were at risk for losing functional independence.


Eligibility criteria: Inclusion Criteria:

* Men and women between the ages of 55 and 90
* Diagnosed with heart failure (NYHA class II-III)
* Receiving optimal medical therapy
* Sedentary (≤ 30 min/wk structured physical activity)
* Peak VO2 between 10 and 30 mL/kg/min.

Exclusion Criteria:

* Oxygen dependent
* Recent medications changes (within 3 months)
* Fixed-rate pacemakers
* Uncontrolled hypertension
* Type I diabetes
* Organ transplant
* Bariatric surgery
* Renal failure (stage 4 or 5)

Primary outcomes:
measure: Subject Adherence & Compliance
timeFrame: 4 Weeks
measure: One Repetition Maximum (1RM)
timeFrame: 4 Weeks
measure: Senior Fitness Test
timeFrame: 4 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke Center for Living; Wallace Clinic
state: North Carolina
Study officials:
affiliation: Duke University
name: Jason D Allen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01991626: Evaluation of the Effects of an Exogenous Phytase on Iron Absorption From LNS Added to Complementary Foods
Official title: Evaluation of the Effects of an Exogenous Phytase on Iron Absorption From Lipid Nutrient Supplements Added to Complementary Foods
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Iron Deficiency
Lead sponsor: Swiss Federal Institute of Technology
Sponsor class: OTHER
Collaborators: name: DSM Nutritional Products, Inc.
First posted: 2013-11-25
Enrollment: 47
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Previous studies on iron absorption have focused on the effects on the addition of iron absorption enhancers like ascorbic acid and EDTA to a meal and more recently the enzymatic phytic acid removal through phytase. The investigators want here to investigate the effects of fat on iron absorption with and without the addition of exogenous phytase as a potential iron absorption enhancer in lipid nutrient supplements (LNS) products compared to micronutrient powder(MNP) products.

Furthermore the investigators will evaluate the effects of Lipids- on iron absorption to induce the ileal brake by ingestion of a fat emulsion prior to a meal. Increasing the caloric density of a meal by increasing its fat content might enhance iron absorption by delaying gastric emptying, gastric acid secretion and increasing Fe stomach residence time.


Eligibility criteria: Inclusion Criteria:

Reproductive age females 18-45 years

* Normal body mass index (17.5-25 kg/m2)
* No intake of mineral/vitamin supplements 2 weeks before and during the study
* No metabolic or gastrointestinal disorders
* No food allergies or other chronic disorders or eating disorders assessed by self-report
* Having received full oral and written information about the aims and procedures of the study
* Willing to comply with the study procedure
* Having provided oral and written informed consent

Exclusion Criteria:

* Regular intake of medication (except oral contraceptives)
* Blood donation or significant blood loss (accident, surgery) over the past 4 months
* Currently participating in another clinical trial or having participated in another clinical trial during the last 30 days prior to the beginning of this study
* Former participation in a study involving administration of iron stable isotopes
* Subject who cannot be expected to comply with study protocol
* Pregnancy or lactation

Primary outcomes:
measure: Iron bio-availability from Oral Iron Supplements
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: ETH Zürich
name: Michael B Zimmermann, Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Monnard A, Moretti D, Zeder C, Steingotter A, Zimmermann MB. The effect of lipids, a lipid-rich ready-to-use therapeutic food, or a phytase on iron absorption from maize-based meals fortified with micronutrient powders. Am J Clin Nutr. 2017 Jun;105(6):1521-1527. doi: 10.3945/ajcn.116.142976. Epub 2017 May 3.
Clinical trial NCT02000726: Neuroimaging Predictors of Antidepressant Treatment Outcome
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Depression
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2013-12-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Current medical therapies for depression take weeks to achieve full efficacy, and are ineffective in many patients or cause intolerable side effects, emphasizing the need for a deeper understanding of depression and its treatment. Identifying early brain biomarkers of treatments responses seems necessary to improve antidepressant treatment outcome. In this study we aim to detect early brain responses to a fast acting antidepressant-like treatment administered intravenously during a Real-Time Neurofeedback functional magnetic resonance imaging (MRI) Task to predict antidepressant treatment outcome in depression. At completion of the neuroimaging task, participants will enter a placebo-controlled clinical trial with a selective serotonin reuptake inhibitor (SSRI).


Eligibility criteria: Inclusion Criteria:

Inclusion criteria will include Hamilton Depressive Rating Scale (HDRS) scores \>15 and Snaith-Hamilton Pleasure Scale scores (SHAPS) \> 7.

Exclusion Criteria:

suicidal ideation, comorbid conditions that are medical, neurological or psychiatric, pregnancy, use of hormones (including birth control) or use of psychotropic agents. We will only permit certain past anxiety disorder diagnoses, including generalized anxiety, panic, agoraphobia, social phobia.

We will also exclude left-handed individuals and patients who have used any centrally acting medications, nicotine, or recreational drugs within the past 2 months.

Primary outcomes:
measure: Blood-oxygen-level dependent (BOLD) responses during the Real-Time Neurofeedback Task.
timeFrame: BOLD responses will be assessed at baseline and depression severity will be assessed at baseline
Secondary outcomes:
measure: Depression severity assessed with several depressive questionnaires.
timeFrame: Every two weeks until the end of the trial (16 weeks total), or until the participants leave the study.
Other outcomes:
measure: Neuropsychological functioning of patients with depression
timeFrame: At baseline
measure: BDNF Val66Met single nucleotide polymorphism(SNP)genotyping
timeFrame: At baseline
Locations:
city: Ann Arbor
country: United States
facility: Department of Psychiatry
state: Michigan
Study officials:
References:
Clinical trial NCT02954926: Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis
Official title: Effect of Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Neonatal Sepsis
Lead sponsor: Hormozgan University of Medical Sciences
Sponsor class: OTHER
First posted: 2016-11-04
Enrollment: 92
Sex: ALL
Minimum age (years): 1
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Majority of healthcare authorities believe that due to the methodological weakness and small number of patients in conducted therapeutic trials, the evidences are insufficient to support the efficacy of intravenous immunoglobulin (IVIG) in prevention of preterm neonatal sepsis. The objective of this research is to determine the effect of intravenous immunoglobulin in prevention of preterm neonatal sepsis.


Eligibility criteria: Inclusion Criteria:

* Born alive before 37 weeks of pregnancy (preterm neonates)
* Under 2500 g at birth

Exclusion Criteria:

* lethal anomaly
* congenital heart disease
* TORCH infection
* severe asphyxia

Primary outcomes:
measure: Mortality
timeFrame: 7 days
Secondary outcomes:
measure: Total number of days of hospitalization
timeFrame: 7 days
measure: Intraventricular Hemorrhage
timeFrame: 7 days
measure: Necrotizing enterocolitis
timeFrame: 7 days
measure: Bronchopulmonary dysplasia
timeFrame: 7 days
Other outcomes:
Locations:
city: Bandar Abbas
country: Iran, Islamic Republic of
facility: Shahid Mohammadi hospital
state: Hormozgan
Study officials:
References:
Clinical trial NCT04150926: The Effect of Black Currant on Postprandial Glucose Metabolism
Official title: The Effect of Black Currant on Postprandial Glucose Metabolism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postprandial Hyperglycemia
Prediabetic State
Keywords: berries
black currant
glucose
glycemia
quinoa
Lead sponsor: University of Eastern Finland
Sponsor class: OTHER
Collaborators: name: Savonia University of Applied Sciences
name: Regional Development Company SavoGrow
First posted: 2019-11-05
Enrollment: 26
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Meal studies in randomised order
Primary purpose: PREVENTION

Brief summary: The study examines the effect of black currant on glucose and insulin concentrations after a meal. In addition, the cytokine and free fatty acids levels are of interest.

Detailed description: The study examines the effect of black currant on glucose and insulin concentrations after a meal.

Healthy (n= 30) volunteers are recruited to participate in four consecutive visits in the research laboratory, when four meals are served in randomised order. Meals are: black currant puree, black currant and quinoa based snack, quinoa base and liquid containing glucose, fructose and sucrose. The meals contain the same amount of carbohydrates.

In addition to glucose and insulin concentration, cytokine and free fatty acid concentrations are measured after each meal.

Eligibility criteria: Inclusion Criteria:

* age: 25-65 years
* BMI: 20-28 kg/m2
* Perceived health status: Good

Exclusion Criteria:

* fasting glucose: \> 7.0 mmol/l
* LDL-cholesterol: \> 3.0 mmol/l
* total cholesterol: \> 6.5 mmol/l
* blood pressure : \> 160/100 mmHg
* weight change of \> 5% during previous 6 months or active weightreduction
* no serious chronic diseases
* one exception of the exclusion criteria maybe accepted after the MD consideration

Primary outcomes:
measure: Glucose concentration
timeFrame: 0 minutes until 180 minutes
measure: Insulin concentration
timeFrame: 0 minutes until 180 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Kuopio
country: Finland
facility: University of Eastern Finland
Study officials:
References:
Clinical trial NCT01970826: Compare Sterilized Clean vs Sterilized Aseptic Dental Implant Surgery
Official title: Sterilized Aseptic Versus Sterilized Clean Field for Dental Implant Placement - Randomized Clinical Control Trial for Non-inferiority Comparison
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Endosseous Dental Implant Failure
Bone Loss
Keywords: aseptic sterilized field
clean sterilized field
dental implants
Surgery
Lead sponsor: Implantology Institute
Sponsor class: OTHER
First posted: 2013-10-28
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: In patients that require dental implants , does performing the surgery in clean sterile field compared to aseptic field, produces more post-operatory complications, implant morbidity or patient discomfort ?

Detailed description: The investigators intend to compare two types of operatory room preparation (aseptic versus clean), used world wide, for placing dental implants.

The investigators want to see if it has impact on post-operatory healing, osseointegration and success rate of dental implants.

Before Study begins the investigators will perform inter-observer agreement in surgical preparation of the surgical suite, implant placements and operatory-room behavior.

Eligibility criteria: Inclusion Criteria:

* All surgeries schedule for implant placement

Exclusion Criteria:

* Surgeries not made with local anesthesia

Primary outcomes:
measure: Post-Operatory Complications
timeFrame: From Implant Placement (Baseline) to 4 weeks after (T1)
measure: Osseointegration
timeFrame: At 8 weeks (T2) after Baseline
Secondary outcomes:
measure: Marginal bone loss
timeFrame: At Final Restoration placement - Expected Average of 12 Weeks after baseline
measure: Patient Satisfaction
timeFrame: At 2 weeks
Other outcomes:
Locations:
city: Lisbon
country: Portugal
facility: University of Lisbon, School of Dentistry
Study officials:
affiliation: University of Lisbon, College of Dentistry
name: Andre Chen, Msc
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Lisbon, College of Dentistry
name: João Caramês, Phd
role: STUDY_DIRECTOR
affiliation: University of Lisbon, School of Dentistry
name: João Canta, Msc
role: STUDY_CHAIR
affiliation: University of Lisbon, College of Dentistry
name: Helena Francisco, Msc
role: STUDY_CHAIR
References:
Clinical trial NCT06325826: The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
Official title: The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Hepatocellular Carcinoma
Lead sponsor: Egyptian Liver Hospital
Sponsor class: OTHER
First posted: 2024-03-22
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved SVR for HCV after DAAs

Brief summary: This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct acting antiviral drugs and determine the group of these patients who require intensified surveillance.


Eligibility criteria: Inclusion Criteria:

* Adult patients aged 18 years or older.
* Patients with compensated advanced chronic liver disease (cACLD) according to Baveno VI consensus (F3-F4)
* achieved SVR for HCV after DAAs.

Exclusion Criteria:

* Previous interferon (IFN) treatment.
* Hepatitis B virus (HBV) or human immune-deficiency virus (HIV) co-infection.
* Current hepatocellular carcinoma (HCC) or other malignancies.
* Previous history of HCC or HCC intervention.
* Liver cell failure, liver transplantation or renal impairment

Primary outcomes:
measure: Hepatocellular Carcinoma
timeFrame: 24 month
Secondary outcomes:
Other outcomes:
Locations:
city: Talkha
country: Egypt
facility: Egyptian Liver Hospital
state: Dakahlia
Study officials:
References:
Clinical trial NCT00163826: Spinal Clearance Study: Expediting the Spinal Clearance Process in the Major Trauma Patient
Official title: Optimisation of Patient Management Through Expediting the Spinal Clearance Process in the Major Trauma Patient
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Trauma
Traumatic Brain Injury
Spinal Injuries
Keywords: cervical spine injury
multiple trauma
Lead sponsor: Bayside Health
Sponsor class: OTHER_GOV
Collaborators: name: Victorian Trauma Foundation
First posted: 2005-09-14
Enrollment: 299
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospital trauma patients

Brief summary: The Alfred Hospital receives approximately 40% of the major trauma patients in Victoria, all of whom are at risk for spinal injuries. The potential for spinal injuries necessitates the undertaking of appropriate spinal investigations, and a delay in the completion of these investigations exposes the patient to the risk of a missed diagnosis of spinal instability and of complications of immobility; the potential spinal patient is required to wear a neck collar and be nursed lying flat whilst awaiting the completion and the appropriate documentation of spinal X-ray investigations.

The purpose of this study is to identify the issues causing a delay in the process of the completion of the appropriate spinal investigations and the documentation of the results.

The outcome of the proposed research will be the development of a clinical management protocol to expedite the process, with the aim of optimising patient care and reducing complications.


Eligibility criteria: Inclusion Criteria:

* Major trauma patients

Exclusion Criteria:

* Patients not subjected to spinal position restrictions on admission
* Patients deceased prior to spinal clearance
* Patients transferred to another centre prior to spinal clearance

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Melbourne
country: Australia
facility: Bayside Health
state: Victoria
Study officials:
affiliation: Bayside Health
name: Helen M Ackland, MHSc
role: PRINCIPAL_INVESTIGATOR
References: